The iCMLf/HARMONY CML Genomics Project has submitted groundbreaking research to the ASH 2025 Annual Meeting, showcasing how global collaboration is driving progress toward more personalised CML treatment.

We are delighted to share that the iCMLf, together with the HARMONY Foundation, has submitted new research to the upcoming American Society of Hematology (ASH) Annual Meeting, the world’s leading platform for advances in blood cancers. This work is part of the iCMLf Genomics Alliance in partnership with HARMONY, a unique global collaboration pooling genomic and clinical data from CML patients worldwide. With over 1,100 cases already in the shared database, this represents one of the largest international resources for understanding the genetic landscape of CML.

This first analysis focuses on nearly 500 patients treated with imatinib, exploring how genetic changes present at diagnosis may influence future treatment responses. By uniting expertise and data from 12 centres across Europe, Asia, the Middle East, Australia, and North America, this project is building the evidence needed to personalise treatment strategies for people living with CML. The iCMLf and HARMONY’s collaboration in this international effort is helping to shape the next generation of CML care—ensuring research translates into better outcomes for patients worldwide.

Thanks to all the authors and collaborators.